ADVERTISEMENT The M1M is an automated analyzer designed for use with the Company's BioVerify test kits for the detection of botulinum neurotoxins, anthrax, ricin, and staphylococcal enterotoxins A and B, among others. The analyzer has also been designed for use with the tests currently being manufactured by the Company for the United States Department of Defense. The system has easy- to-use sample handling and can detect biological agents quickly and with high sensitivity. System software reports positive or negative results automatically in a standard format. The M1M Analyzer was built with specification and configuration inputs from the Company's customers and is designed to meet the needs of field, mobile and centralized laboratories.
"The introduction of the M1M furthers BioVeris' commitment to enhance the safety of the civilian and armed forces populations throughout the world," said Samuel J. Wohlstadter, BioVeris' Chief Executive Officer. "The sensitivity and flexibility of BV technology enables us to provide products that we believe meet testing needs in the field or for use in the laboratory. We expect the M1M to be a valuable tool for existing and potential homeland security and defense customers in the United States and Europe."
BioVeris currently provides a range of detection products and services to numerous agencies within militaries and departments of public health, including the U.S. Department of Defense, U.S. Food and Drug Administration, and the Swedish Defense Research Agency.
The M1M Analyzer will also be demonstrated at the British Health Protection Agency's "Meeting the Challenges of Infectious Diseases through Advances in Developing Technologies" conference being held June 21 and 22 in London. More information on M-SERIES products and the M1M Analyzer may be found on the Company's website www.bioveris.com.
BioVeris Corporation is an international health care company dedicated to the commercialization, directly and through collaborations and alliances, of innovative, technology-based products and services intended to improve the quality of life. The company applies its expertise in biotechnology, detection systems, and clinical diagnostics to the development of new and proprietary products and pursues collaborative arrangements toentify new health care product opportunities, accelerate product development, and enhance its global capabilities and competitiveness. BioVeris is headquartered in Gaithersburg, Maryland. More information about the company can be found at www.bioveris.com.
This press release contains forward-looking statements within the meaning of the federal securities laws that relate to future events or BioVeris' future financial performance. All statements in this press release that are not historical facts, including any statements about the markets, potential markets, market growth, the prospects for and utility of a new product in the market and the Company's ability to compete in the biodefense, life science research, food testing and clinical diagnostic markets, are herebyentified as "forward-looking statements." The words "may," "should," "will," "expect," "could," "anticipate," "believe," "estimate," "plan," "intend" and similar expressions have been used toentify certain of the forward-looking statements. In this press release, BioVeris has based these forward-looking statements on management's current expectations, estimates and projections and they are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements should, therefore, be considered in light of various important factors, including changes in BioVeris' strategy and business plans; BioVeris' ability to develop and introduce new or enhanced products; the utility and customer acceptance of new products; the availability of financing and financial resources in the amounts, at the times and on the terms required to support BioVeris' future business; and changes in general economic, business and industry conditions. The foregoing sets forth some, but not all, of the factors that could impact upon BioVeris' ability to achieve results described in any forward-looking statements. A more complete description of the risks applicable to BioVeris is provided in the Company's filings with the Securities and Exchange Commission (SEC) available at the SEC's web site at www.sec.gov. Investors are cautioned not to place undue reliance on these forward-looking statements. Investors also should understand that is not possible to predict orentify all risk factors and that neither this list nor the factorsentified in BioVeris' SEC filings should be considered a complete statement of all potential risks and uncertainties. BioVeris has no obligation to publicly update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this press release.
------------------------------------------------------------------------ Source: BioVeris Corporation